Introduction {#sec0001}
============

Around the start of the European Symposium on Ultrasound Contrast Agents, ultrasound-responsive cavitation nuclei were reported to have therapeutic potential. Thrombolysis was reported to be accelerated *in vitro* ([@bib0271]), and cultured cells were transfected with plasmid DNA ([@bib0023]). Since then, many research groups have investigated the use of cavitation nuclei for multiple forms of therapy, including tissue ablation and drug and gene delivery. In the early years, the most widely investigated cavitation nuclei were gas microbubbles, ∼1--10 µm in diameter and coated with a stabilizing shell, whereas today both solid and liquid nuclei, which can be as small as a few hundred nanometers, are also being investigated. Drugs can be co-administered with the cavitation nuclei or loaded in or on them ([@bib0165]; [@bib0144]). The diseases that can be treated with ultrasound-responsive cavitation nuclei include but are not limited to cardiovascular disease and cancer ([@bib0269]; [@bib0213]), the current leading causes of death worldwide according to the World Health Organization ([@bib0207]). This review focuses on the latest insights into cavitation nuclei for therapy and drug delivery from the physical and biological mechanisms of bubble--cell interaction to pre-clinical (both *in vitro* and *in vivo*) and clinical (time span: 2014-2019) studies, with particular emphasis on the key clinical applications. The applications covered in this review are the treatment of tumors, immunotherapy, blood--brain barrier (BBB) and blood--spinal cord barrier, dissolution of clots, cardiovascular drug delivery and treatment of bacterial infections.

Cavitation nuclei for therapy {#sec0002}
=============================

The most widely used cavitation nuclei are phospholipid-coated microbubbles with a gas core. For the 128 pre-clinical studies included in the treatment sections of this review, the commercially available and clinically approved Definity (Luminity in Europe; octafluoropropane gas core, phospholipid coating) ([@bib0062]; [@bib0206]) microbubbles were the most frequently used (in 22 studies). Definity was used for studies on all applications discussed here, mostly for opening the BBB (12 studies). SonoVue (Lumason in the United States) is commercially available and clinically approved as well (sulfur hexafluoride gas core, phospholipid coating) ([@bib0178]; [@bib0206]) and was used in a total of 14 studies for treatment of non-brain tumors (*e.g.,* [@bib0301]), BBB opening (*e.g.,* [@bib0102]) and sonobactericide (*e.g.*, [@bib0123]). Other commercially available microbubbles were used that are not clinically approved, such as BR38 ([@bib0244]) in the study by [@bib0288] and MicroMarker ([@bib0283]) in the study by [@bib0272]. Custom-made microbubbles are as diverse as their applications, with special characteristics tailored to enhance different therapeutic strategies. Different types of gasses were used as the core such as air (*e.g.,* [@bib0077]), nitrogen (*e.g.,* [@bib0069])~,~ oxygen (*e.g.,* [@bib0087]), octafluoropropane (*e.g.,* [@bib0214]), perfluorobutane (*e.g.,* [@bib0067]), sulfur hexafluoride ([@bib0022]; [@bib0119]) or a mixture of gases such as nitric oxide and octafluoropropane ([@bib0270]) or sulfur hexafluoride and oxygen ([@bib0191]). While fluorinated gases improve the stability of phospholipid-coated microbubbles ([@bib0237]), other gases can be loaded for therapeutic applications, such as oxygen for treatment of tumors ([@bib0191]; [@bib0087]; [@bib0205]) and nitric oxide ([@bib0141]; [@bib0270]) and hydrogen gas ([@bib0113]) for treatment of cardiovascular disease. The main phospholipid component of custom-made microbubbles is usually a phosphatidylcholine such as 1,2-dipalmitoyl-*sn*-glycero-3-phosphocholine (DPPC), used in 13 studies (*e.g.,* [@bib0067]; [@bib0022]; [@bib0049]; [@bib0096]), or 1,2-distearoyl-*sn*-glycero-3-phosphocholine (DSPC), used in 18 studies (*e.g.,* [@bib0139]; [@bib0031]; [@bib0072]; [@bib0103]; [@bib0214]). These phospholipids are popular because they are also the main components in Definity ([@bib0062]) and SonoVue/Lumason ([@bib0178]), respectively. Another key component of the microbubble coating is a polyethylene glycol (PEG)ylated emulsifier such as polyoxyethylene (40) stearate (PEG40-stearate; *e.g.,* [@bib0139]) or the most frequently used 1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine-*N*-carboxy(polyethylene glycol) (DSPE--PEG2000; *e.g.,* [@bib0028]), which is added to inhibit coalescence and to increase the *in vivo* half-life ([@bib0086]). In general, two methods are used to produce custom-made microbubbles: mechanical agitation (*e.g.,* [@bib0117]) and probe sonication (*e.g.,* [@bib0027]). Both methods produce a population of microbubbles that is polydisperse in size. Monodispersed microbubbles produced by microfluidics have recently been developed, and are starting to gain attention for pre-clinical therapeutic studies. [@bib0069] used monodisperse microbubbles to treat ischemic stroke.

Various therapeutic applications have inspired the development of novel cavitation nuclei, which is discussed in depth in the companion review by [@bib0265]. To improve drug delivery, therapeutics can be either co-administered with or loaded onto the microbubbles. One strategy for loading is to create microbubbles stabilized by drug-containing polymeric nanoparticles around a gas core ([@bib0261]). Another strategy is to attach therapeutic molecules or liposomes to the outside of microbubbles, for example, by biotin--avidin coupling ([@bib0067]; [@bib0192]; [@bib0205]). Echogenic liposomes can be loaded with different therapeutics or gases and have been studied for vascular drug delivery ([@bib0270]), treatment of tumors ([@bib0053]) and sonothrombolysis ([@bib0252]). Acoustic Cluster Therapy (ACT) combines Sonazoid microbubbles with droplets that can be loaded with therapeutics for treatment of tumors ([@bib0150]). The cationic microbubbles utilized in the treatment sections of this review were used mostly for vascular drug delivery, with genetic material loaded on the microbubble surface by charge coupling (*e.g.,* [@bib0040]). Besides phospholipids and nanoparticles, microbubbles can also be coated with denatured proteins such as albumin. Optison ([@bib0212]) is a commercially available and clinically approved ultrasound contrast agent that is coated with human albumin and used in studies on treatment of non-brain tumors ([@bib0300]), BBB opening ([@bib0152]; [@bib0219]) and immunotherapy ([@bib0263]). Nano-sized particles cited in this review have been used as cavitation nuclei for treatment of tumors, such as nanodroplets (*e.g.,* [@bib0041]) and nanocups ([@bib0203]); for BBB opening (nanodroplets; [@bib0298]); and for sonobactericide (nanodroplets; [@bib0106]).

Bubble--cell interaction {#sec0003}
========================

Physics {#sec0004}
-------

The physics of the interaction between bubbles or droplets and cells are described as these are the main cavitation nuclei used for drug delivery and therapy.

### Physics of microbubble--cell interaction {#sec0005}

Being filled with gas and/or vapor makes bubbles highly responsive to changes in pressure, and hence, exposure to ultrasound can cause rapid and dramatic changes in their volume. These volume changes in turn give rise to an array of mechanical, thermal and chemical phenomena that can significantly influence the bubbles' immediate environment and mediate therapeutic effects. For the sake of simplicity, these phenomena are discussed in the context of a single bubble. It is important to note, however, that biological effects are typically produced by a population of bubbles and the influence of inter-bubble interactions should not be neglected.

#### Mechanical effects {#sec0006}

A bubble in a liquid is subject to multiple competing influences: the driving pressure of the imposed ultrasound field; the hydrostatic pressure imposed by the surrounding liquid; the pressure of the gas and/or vapor inside the bubble; surface tension and the influence of any coating material; the inertia of the surrounding fluid; and damping caused by the viscosity of the surrounding fluid and/or coating, thermal conduction and/or acoustic radiation.

The motion of the bubble is determined primarily by the competition between the liquid inertia and the internal gas pressure. This competition can be characterized by using the Rayleigh--Plesset equation for bubble dynamics to compare the relative contributions of the terms describing inertia and pressure to the acceleration of the bubble wall ([@bib0092]):$$\overset{¨}{R} = - \left( {\frac{3}{2}\frac{{\overset{˙}{R}}^{2}}{R}} \right) + \left( \frac{p_{G}\left( R \right) + p_{\infty}\left( t \right) - \frac{2\sigma}{R}}{\rho_{L}R} \right) = \text{IF} + \text{PF}$$where *R* is the time-dependent bubble radius with initial value *R*~o~, *p*~G~ is the pressure of the gas inside the bubble, *p*~∞~ is the combined hydrostatic and time-varying pressure in the liquid, σ is the surface tension at the gas--liquid interface, *ρ*~L~ is the liquid density, IF is inertia factor and PF the pressure factor.

[@bib0092], [@bib0093]) identified two scenarios: If the PF is dominant when the bubble approaches its minimum size, then the bubble will undergo sustained volume oscillations. If the inertia term is dominant (IF), then the bubble will undergo inertial collapse, similar to an empty cavity, after which it may rebound or it may disintegrate. Which of these scenarios occurs is dependent upon the bubble expansion ratio *R*~max~*/R*~o~ and, hence, the bubble size and the amplitude and frequency of the applied ultrasound field.

Both inertial and non-inertial bubble oscillations can give rise to multiple phenomena that affect the bubble\'s immediate environment and hence are important for therapy. These include:1.Direct impingement: Even at moderate amplitudes of oscillation, the acceleration of the bubble wall may be sufficient to impose significant forces on nearby surfaces, easily deforming fragile structures such as biological cell membranes ([@bib0280]; [@bib0154]) and blood vessel walls ([@bib0046]).2.Ballistic motion: In addition to oscillating, the bubble may undergo translation as a result of the pressure gradient in the fluid generated by a propagating ultrasound wave (primary radiation force). Because of their high compressibility, bubbles may travel at significant velocities, sufficient to push them toward targets for improved local deposition of a drug ([@bib0058]) or to penetrate biological tissue ([@bib0044]; [@bib0019]; [@bib0002]).3.Microstreaming: When a structure oscillates in a viscous fluid there will be a transfer of momentum as a result of interfacial friction. Any asymmetry in the oscillation will result in a net motion of that fluid in the immediate vicinity of the structure known as *microstreaming* ([@bib0143]). This motion will in turn impose shear stresses upon any nearby surfaces, as well as increase convection within the fluid. Because of the inherently non-linear nature of bubble oscillations (eqn \[1\]), both non-inertial and inertial cavitation can produce significant microstreaming, resulting in fluid velocities on the order of 1 mm/s ([@bib0220]). If the bubble is close to a surface then it will also exhibit non-spherical oscillations, which increases the asymmetry and hence the microstreaming even further ([@bib0208]; [@bib0184]).4.Microjetting: Another phenomenon associated with non-spherical bubble oscillations near a surface is the generation of a liquid jet during bubble collapse. If there is sufficient asymmetry in the acceleration of the fluid on either side of the collapsing bubble, then the more rapidly moving fluid may deform the bubble into a toroidal shape, causing a high-velocity jet to be emitted on the opposite side. Microjetting has been reported to be capable of producing pitting even in highly resilient materials such as steel ([@bib0204]; [@bib0029]). However, as both the direction and velocity of the jet are determined by the elastic properties of the nearby surface, its effects in biological tissue are more difficult to predict ([@bib0155]). Nevertheless, as reported by [@bib0046], in many cases a bubble will be sufficiently confined that microjetting will have an impact on surrounding structures regardless of jet direction.5.Shock waves: An inertially collapsing cavity that results in supersonic bubble wall velocities creates a significant discontinuity in the pressure in the surrounding liquid leading to the emission of a shock wave, which may impose significant stresses on nearby structures.6.Secondary radiation force: At smaller amplitudes of oscillation, a bubble will also generate a pressure wave in the surrounding fluid. If the bubble is adjacent to a surface, interaction between this wave and its reflection from the surface leads to a pressure gradient in the liquid and a secondary radiation force on the bubble. As with microjetting, the elastic properties of the boundary will determine the phase difference between the radiated and reflected waves and, hence, whether the bubbles move toward or away from the surface. Motion toward the surface may amplify the effects of phenomena 1, 3 and 6.

#### Thermal effects {#sec0007}

As described above, an oscillating microbubble will re-radiate energy from the incident ultrasound field in the form of a spherical pressure wave. In addition, the non-linear character of the microbubble oscillations will lead to the re-radiation of energy over a range of frequencies. At moderate driving pressures, the bubble spectrum will contain integer multiples (harmonics) of the driving frequency; and at higher pressures, also fractional components (sub- and ultraharmonics). In biological tissue, absorption of ultrasound increases with frequency and this non-linear behavior thus also increases the rate of heating ([@bib0115]; [@bib0118]). Bubbles will also dissipate energy as a result of viscous friction in the liquid and thermal conduction from the gas core, the temperature of which increases during compression. Which mechanism is dominant depends on the size of the bubble, the driving conditions and the viscosity of the medium. Thermal damping is, however, typically negligible in biomedical applications of ultrasound as the time constant associated with heat transfer is much longer than the period of the microbubble oscillations ([@bib0226]).

#### Chemical effects {#sec0008}

The temperature rise produced in the surrounding tissue will be negligible compared with that occurring inside the bubble, especially during inertial collapse when it may reach several thousand Kelvin ([@bib0090]). The gas pressure similarly increases significantly. Although only sustained for a very brief period, these extreme conditions can produce highly reactive chemical species, in particular reactive oxygen species (ROS), as well as the emission of electromagnetic radiation (sonoluminescence). ROS have been reported to play a significant role in multiple biological processes ([@bib0296]), and both ROS and sonoluminescence may affect drug activity ([@bib0236]; [@bib0275]; [@bib0026]).

### Physics of droplet--cell interaction {#sec0009}

Droplets consist of an encapsulated quantity of a volatile liquid, such as perfluorobutane (boiling point: --1.7°C) or perfluoropentane (boiling point: 29°C), which is in a superheated state at body temperature. Superheated state means that although the volatile liquids have a boiling point below 37°C, these droplets remain in the liquid phase and do not exhibit spontaneous vaporization after injection. Vaporization can be achieved instead by exposure to ultrasound of significant amplitude via a process known as acoustic droplet vaporization (ADV) ([@bib0153]). Before vaporization, the droplets are typically one order of magnitude smaller than the emerging bubbles, and the perfluorocarbon is inert and biocompatible ([@bib0032]). These properties enable a range of therapeutic possibilities ([@bib0248]; [@bib0161]). For example, unlike microbubbles, small droplets may extravasate from the leaky vessels into tumor tissue because of the enhanced permeability and retention (EPR) effect ([@bib0177]; [@bib0157]; [@bib0181]), and then be turned into bubbles by ADV ([@bib0231]; [@bib0145]). Loading the droplets with a drug enables local delivery ([@bib0231]) by way of ADV. The mechanism behind this is that the emerging bubbles give rise to similar radiation forces and microstreaming as described earlier in the Physics of the Microbubble--Cell Interaction. It should be noted that oxygen is taken up during bubble growth ([@bib0230]), which could lead to hypoxia.

The physics of the droplet--cell interaction is largely governed by the ADV. In general, it has been observed that ADV is promoted by the following factors: large peak negative pressures ([@bib0153]), usually obtained by strong focusing of the generated beam, high frequency of the emitted wave and a relatively long distance between the transducer and the droplet. Another observation that has been made with micrometer-sized droplets is that vaporization often starts at a well-defined nucleation spot near the side of the droplet where the acoustic wave impinges ([@bib0256]). These facts can be explained by considering the two mechanisms that play a role in achieving a large peak negative pressure inside the droplet: acoustic focusing and non-linear ultrasound propagation ([@bib0257]). In the following, lengths and sizes are related to the wavelength, that is, the distance traveled by a wave in one oscillation (*e.g.,* a 1-MHz ultrasound wave that is traveling in water with a wave speed, *c*, of 1500 m/s has a wavelength, *w* (m), of *c*/*f* = 1500/10^6^ = 0.0015, that is, 1.5 mm.

#### Acoustic focusing {#sec0010}

Because the speed of sound in perfluorocarbon liquids is significantly lower than that in water or tissue, refraction of the incident wave will occur at the interface between these fluids, and the spherical shape of the droplet will give rise to focusing. The assessment of this focusing effect is not straightforward because the traditional way of describing these phenomena with rays that propagate along straight lines (the ray approach) holds only for objects that are much larger than the applied wavelength. In the current case, the frequency of a typical ultrasound wave used for insonification is in the order of 1--5 MHz, yielding wavelengths in the order of 1500--300 µm, while a droplet will be smaller by two to four orders of magnitude. In addition, using the ray approach, the lower speed of sound in perfluorocarbon would yield a focal spot near the backside of the droplet, which is in contradiction to observations. The correct way to treat the focusing effect is to solve the full diffraction problem by decomposing the incident wave, the wave reflected by the droplet and the wave transmitted into the droplet into a series of spherical waves. For each spherical wave, the spherical reflection and transmission coefficients can be derived. Superposition of all the spherical waves yields the pressure inside the droplet. Nevertheless, when this approach is only applied to an incident wave with the frequency that is emitted by the transducer, this will lead neither to the right nucleation spot nor to sufficient negative pressure for vaporization. Nanoscale droplets may be too small to make effective use of the focusing mechanism, and ADV is therefore less dependent on the frequency.

#### Non-linear ultrasound propagation {#sec0011}

High pressure amplitudes, high frequencies and long propagation distances all promote non-linear propagation of an acoustic wave ([@bib0110]). In the time domain, non-linear propagation manifests as an increasing deformation of the shape of the ultrasound wave with distance traveled. In the frequency domain, this translates to increasing harmonic content, that is, frequencies that are multiples of the driving frequency. The total incident acoustic pressure *p*(*t*) at the position of a nanodroplet can therefore be written as$$p\left( t \right) = \sum\limits_{n\; = \; 1}^{\infty\;}a_{n}\text{cos}\left( {n\omega t + \phi_{n}} \right)$$where *n* is the number of a harmonic, *a~n~* and *ϕ~n~* are the amplitude and phase of this harmonic and *ω* is the angular frequency of the emitted wave. The wavelength of a harmonic wave is a fraction of the emitted wavelength.

The aforementioned effects are both important in the case of ADV and should therefore be combined. This implies that first the amplitudes and phases of the incident non-linear ultrasound wave at the droplet location should be computed. Next, for each harmonic, the diffraction problem should be solved in terms of spherical harmonics. Adding the diffracted waves inside the droplet with the proper amplitude and phase will then yield the total pressure in the droplet. [Figure 1](#fig0001){ref-type="fig"} illustrates that the combined effects of non-linear propagation and diffraction can cause a dramatic amplification of the peak negative pressure in the micrometer-sized droplet, sufficient for triggering droplet vaporization ([@bib0256]). Moreover, the location of the negative pressure peak also agrees with the observed nucleation spot.Fig. 1Combined effect of non-linear propagation and focusing of the harmonics in a perfluoropentane micrometer-sized droplet. The emitted ultrasound wave has a frequency of 3.5 MHz and a focus at 3.81 cm, and the radius of the droplet is 10 µm for ease of observation. The pressures are given on the axis of the droplet along the propagating direction of the ultrasound wave, and the *shaded area* indicates the location of the droplet. Reprinted with permission from [@bib0256].Fig 1

After vaporization has started, the growth of the emerging bubble is limited by inertia and heat transfer. In the absence of the heat transfer limitation, the inertia of the fluid that surrounds the bubble limits the rate of bubble growth, which is linearly proportional to time and inversely proportional to the square root of the density of the surrounding fluid. When inertia is neglected, thermal diffusion is the limiting factor in the transport of heat to drive the endothermic vaporization process of perfluorocarbon, causing the radius of the bubble to increase with the square root of time. In reality, both processes occur simultaneously, where the inertia effect is dominant at the early stage and the diffusion effect is dominant at the later stage of bubble growth. The final size that is reached by a bubble depends on the time that a bubble can expand, that is, on the duration of the negative cycle of the insonifying pressure wave. It is therefore expected that lower insonification frequencies give rise to larger maximum bubble size. Thus, irrespective of their influence on triggering ADV, lower frequencies would lead to more violent inertial cavitation effects and cause more biological damage, as experimentally observed for droplets with a radius in the order of 100 nm ([@bib0035]).

Biological mechanisms and bio-effects of ultrasound-activated cavitation nuclei {#sec0012}
-------------------------------------------------------------------------------

The biological phenomena of sonoporation (*i.e.,* membrane pore formation), stimulated endocytosis and opening of cell--cell contacts and the bio-effects of intracellular calcium transients, ROS generation, cell membrane potential change and cytoskeleton changes have been observed for several years ([@bib0269]; [@bib0144]; [@bib0166]; [@bib0229]). However, other bio-effects induced by ultrasound-activated cavitation nuclei have recently been discovered. These include membrane blebbing as a recovery mechanism for reversible sonoporation (both for ultrasound-activated microbubbles [@bib0167] and upon ADV [@bib0228]), extracellular vesicle formation ([@bib0315]), suppression of efflux transporter P-glycoprotein ([@bib0052]; [@bib0015]) and BBB (blood--brain barrier) transporter genes ([@bib0194]). At the same time, more insight has been gained into the origin of the bio-effects, largely through the use of live cell microscopy. For sonoporation, real-time membrane pore opening and closure dynamics were revealed with pores \<30 µm^2^ closing within 1 min, while pores \>100 µm^2^ did not reseal ([@bib0122]) as well as immediate rupture of filamentary actin at the pore location ([@bib0047]) and correlation of intracellular ROS levels with the degree of sonoporation ([@bib0129]). Real-time sonoporation and opening of cell--cell contacts in the same endothelial cells have been reported as well for a single example ([@bib0114]). The applied acoustic pressure was found to determine uptake of model drugs *via* sonoporation or endocytosis in another study ([@bib0059]). Electron microscopy revealed formation of transient membrane disruptions and permanent membrane structures, that is, caveolar endocytic vesicles, upon ultrasound and microbubble treatment ([@bib0317]). A study by [@bib0085] revealed that enhanced clathrin-mediated endocytosis and fluid-phase endocytosis occur through distinct signaling mechanisms upon ultrasound and microbubble treatment. The majority of these bio-effects have been observed in *in vitro* models using largely non-endothelial cells and may therefore not be directly relevant to *in vivo* tissue, where intravascular micron-sized cavitation nuclei will only have contact with endothelial cells and circulating blood cells. On the other hand, the mechanistic studies by [@bib0027], [@bib0028]) and [@bib0313] do reveal translation from *in vitro* to *in vivo*. In these studies, ultrasound-activated microbubbles were found to induce a shear-dependent increase in intravascular adenosine triphosphate (ATP) from both endothelial cells and erythrocytes, an increase in intramuscular nitric oxide and downstream signaling through both nitric oxide and prostaglandins, which resulted in augmentation of muscle blood flow. Ultrasound settings were similar, namely, 1.3 MHz, mechanical index (MI) 1.3 for [@bib0027], [@bib0028]) and 1 MHz, MI 1.5 for [@bib0313], with MI defined as MI = *P*~--~/ $\sqrt{f}$, where *P\_* is the derated peak negative pressure of the ultrasound wave (in MPa) and *f* the center frequency of the ultrasound wave (in MHz).

Whether or not there is a direct relationship between the type of microbubble oscillation and specific bio-effects remains to be elucidated, although more insight has been gained through ultrahigh-speed imaging of the microbubble behavior in conjunction with live cell microscopy. For example, there seems to be a microbubble excursion threshold above which sonoporation occurs ([@bib0114]). [@bib0279] further found that displacement of targeted microbubbles enhanced reversible sonoporation and preserved cell viability, whilst microbubbles that did not displace were identified as the main contributors to cell death.

All of the aforementioned biological observations, mechanisms and effects relate to eukaryotic cells. Study of the biological effects of cavitation on, for example, bacteria is in its infancy, but studies suggest that sonoporation can be achieved in Gram-negative bacteria, with dextran uptake and gene transfection being reported in *Fusobacterium nucleatum* ([@bib0111]). More recent studies have investigated the effect of microbubbles and ultrasound on gene expression ([@bib0169]; [@bib0072]; [@bib0326]). The findings are conflicting because although they all reveal a reduction in expression of genes involved in biofilm formation and resistance to antibiotics, an increase in expression of genes involved with dispersion and detachment of biofilms was also found ([@bib0072]). This cavitation-mediated bio-effect needs further investigation.

Modelling microbubble--cell--drug interaction {#sec0013}
---------------------------------------------

Whilst there have been significant efforts to model the dynamics of ultrasound-driven microbubbles ([@bib0082]; [@bib0071]), less attention has been paid to the interactions between microbubbles and cells or their impact upon drug transport. Currently there are no models that describe the interactions between microbubbles, cells and drug molecules. Several models have been proposed for the microbubble--cell interaction in sonoporation focusing on different aspects: cell expansion and microbubble jet velocity ([@bib0107]), the shear stress exerted on the cell membrane ([@bib0297]; [@bib0070]; [@bib0095]; [@bib0311]; [@bib0054]), microstreaming ([@bib0311]), the shear stress exerted on the cell membrane in combination with microstreaming ([@bib0168]) or other flow phenomena ([@bib0312]; [@bib0238]) generated by an oscillating microbubble. In contrast to the other models, [@bib0183] propose that the microbubble-generated shear stress does not induce pore formation, but is instead due to microbubble fusion with the membrane and subsequent "pull out" of cell membrane lipid molecules by the oscillating microbubble. Models for pore formation (*e.g.,* [@bib0148]) and resealing ([@bib0321]) in cell membranes have also been developed, but these models neglect the mechanism by which the pore is created. There is just one sonoporation dynamics model, developed by [@bib0083], that relates the uptake of the model drug propidium iodide (PI) to the size of the created membrane pore and the pore resealing time for a single cell in an *in vitro* setting. The model describes the intracellular fluorescence intensity of PI as a function of time, *F(t)*, by$$F\left( t \right) = \;\alpha \cdot \pi DC_{0} \cdot r_{o} \cdot \frac{1}{\beta}\left( {1 - e^{- \beta t}} \right)$$where *α* is the coefficient that relates the amount of PI molecules to the fluorescence intensity of PI-DNA and PI-RNA, *D* is the diffusion coefficient of PI, *C*~0~ is the extracellular PI concentration, *r*~0~ is the initial radius of the pore, *β* is the pore re-sealing coefficient and *t* is time. The coefficient α is determined by the sensitivity of the fluorescence imaging system, and if unknown, the equation can still be used because it is the pore size coefficient, *α·πDC*~0~*·r*~0~, that determines the initial slope of the PI uptake pattern and is the scaling factor for the exponential increase. A cell with a large pore will have a steep initial slope of PI uptake, and the maximum PI intensity quickly reaches the plateau value. A limitation of this model is that [eqn (3)](#eqn0003){ref-type="disp-formula"} is based on 2-D free diffusion models, which holds for PI-RNA but not for PI-DNA because the latter is confined to the nucleus. The model is independent of cell type, as Fan et al. have reported agreement with experimental results in both kidney ([@bib0083]) and endothelial cells ([@bib0084]). Other researchers have also used this model for endothelial cell studies and also classified the distribution of both the pore size and pore resealing coefficients using principal component analysis (PCA) to determine whether cells were reversibly or irreversibly sonoporated. In the context of BBB opening, [@bib0120] have modeled the microbubble-generated shear and circumferential wall stress for 5-µm microvessels upon microbubble oscillation at a fixed MI of 0.134 for a range of frequencies (0.5, 1 and 1.5 MHz). The wall stresses were dependent upon microbubble size (range investigated: 2--18 µm in diameter) and ultrasound frequency. [@bib0295] have also modelled the wall shear stress generated by microbubble (2 µm in diameter) destruction at 3 MHz for larger microvessels (200 µm in diameter). The presence of red blood cells was included in the model and was found to cause confinement of pressure and shear gradients to the vicinity of the microbubble. Advances in methods for imaging microbubble--cell interactions will facilitate the development of more sophisticated mechanistic models.

Treatment of tumors (non-brain) {#sec0014}
===============================

The structure of tumor tissue varies significantly from that of healthy tissue which has important implications for its treatment. To support the continuous expansion of neoplastic cells, the formation of new vessels (*i.e.,* angiogenesis) is needed ([@bib0135]). As such, a rapidly developed, poorly organized vasculature with enlarged vascular openings arises. Between these vessels, large avascular regions exist, which are characterized by a dense extracellular matrix, high interstitial pressure, low pH and hypoxia. Moreover, a local immunosuppressive environment is formed, preventing possible anti-tumor activity by the immune system.

Notwithstanding the growing knowledge of the pathophysiology of tumors, treatment remains challenging. Chemotherapeutic drugs are typically administered to abolish the rapidly dividing cancer cells. Yet, their cytotoxic effects are not limited to cancer cells, causing dose-limiting off-target effects. To overcome this hurdle, chemotherapeutics are often encapsulated in nano-sized carriers, that is, nanoparticles, that are designed to specifically diffuse through the large openings of tumor vasculature, while being excluded from healthy tissue by normal blood vessels ([@bib0157]; [@bib0181]). Despite being highly promising in pre-clinical studies, drug-containing nanoparticles have exhibited limited clinical success because of the vast heterogeneity in tumor vasculature ([@bib0024]; [@bib0157]; [@bib0288]). In addition, drug penetration into the deeper layers of the tumor can be constrained by high interstitial pressure and a dense extracellular matrix in the tumor. Furthermore, acidic and hypoxic regions limit the efficacy of radiation- and chemotherapy-based treatments because of biochemical effects ([@bib0197]; [@bib0191]; [@bib0087]). Ultrasound-triggered microbubbles are able to alter the tumor environment locally, thereby improving drug delivery to tumors. These alterations are schematically represented in [Figure 2](#fig0002){ref-type="fig"} and include improving vascular permeability, modifying the tumor perfusion, reducing local hypoxia and overcoming the high interstitial pressure.Fig. 2Ultrasound-activated microbubbles can locally alter the tumor microenvironment through four mechanisms: enhanced permeability, improved contact, reduced hypoxia and altered perfusion. ROS = reactive oxygen species.Fig 2

Several studies have found that ultrasound-driven microbubbles improved delivery of chemotherapeutic agents in tumors, which resulted in increased anti-tumor effects ([@bib0288]; [@bib0261]; [@bib0320]). Moreover, several gene products could be effectively delivered to tumor cells *via* ultrasound-driven microbubbles, resulting in a downregulation of tumor-specific pathways and an inhibition in tumor growth ([@bib0147]; [@bib0325]). [@bib0272] furthermore confirmed that nanoparticle accumulation can be achieved in tumors with low EPR effect. Drug transport and distribution through the dense tumor matrix and into regions with elevated interstitial pressure are often the limiting factors in peripheral tumors. As a result, several reports have indicated that drug penetration into the tumor remained limited after sonoporation, which may impede the eradication of the entire tumor tissue ([@bib0077]; [@bib0288]; [@bib0292]). Alternatively, microbubble cavitation can affect tumor perfusion, as vasoconstriction and even temporary vascular shutdown have been reported *ex vivo* ([@bib0137]) and *in vivo* ([@bib0121]; [@bib0100]; [@bib0309]). These effects were seen at higher ultrasound intensities (\>1.5 MPa) and are believed to result from inertial cavitation leading to violent microbubble collapses. As blood supply is needed to maintain tumor growth, vascular disruption might form a different approach to cease tumor development. Microbubble-induced microvascular damage was able to complement the direct effects of chemotherapeutics and antivascular drugs by secondary ischemia-mediated cytotoxicity, which led to tumor growth inhibition ([@bib0285]; [@bib0117]; [@bib0306]). In addition, a synergistic effect between radiation therapy and ultrasound-stimulated microbubble treatment was observed, as radiation therapy also induces secondary cell death by endothelial apoptosis and vascular damage ([@bib0156]; [@bib0056]). Nevertheless, several adverse effects have been reported because of excessive vascular disruption, including hemorrhage, tissue necrosis and the formation of thrombi ([@bib0100]; [@bib0288]; [@bib0261]).

Furthermore, oxygen-containing microbubbles can provide a local oxygen supply to hypoxic areas, rendering oxygen-dependent treatments more effective. This is of interest for sonodynamic therapy, which is based on the production of cytotoxic ROS by a sonosensitizing agent upon activation by ultrasound in the presence of oxygen ([@bib0191], [@bib0192]; [@bib0205]). As ultrasound can be used to stimulate the release of oxygen from oxygen-carrying microbubbles while simultaneously activating a sonosensitizer, this approach has been reported to be particularly useful for the treatment of hypoxic tumor types ([@bib0191]; [@bib0205]). Additionally, low oxygenation promotes resistance to radiotherapy, which can be circumvented by a momentary supply of oxygen. Based on this notion, oxygen-carrying microbubbles were used to improve the outcome of radiotherapy in a rat fibrosarcoma model ([@bib0087]).

Finally, ultrasound-activated microbubbles promote convection and induce acoustic radiation forces. As such, closer contact with the tumor endothelium and an extended contact time can be obtained ([@bib0139]). Furthermore, these forces may counteract the elevated interstitial pressure present in tumors ([@bib0077]; [@bib0160]; [@bib0300]).

Apart from their ability to improve tumor uptake, microbubbles can be used as ultrasound-responsive drug carriers to reduce the off-target effects of chemotherapeutics. By loading the drugs or drug-containing nanoparticles directly into or onto the microbubbles, a spatial and temporal control of drug release can be obtained, thereby reducing exposure to other parts of the body ([@bib0303]; [@bib0261]). Moreover, several studies have reported improved anti-cancer effects from treatment with drug-coupled microbubbles, compared with a co-administration approach ([@bib0038]; [@bib0261]). Additionally, tumor neovasculature expresses specific surface receptors that can be targeted by specific ligands. Adding such targeting moieties to the surface of (drug-loaded) microbubbles improves site-targeted delivery and has been found to potentiate this effect further ([@bib0022]; [@bib0301]; [@bib0179]).

Phase-shifting droplets and gas-stabilizing solid agents (*e.g.,* nanocups) have the unique ability to benefit from both EPR-mediated accumulation in the "leaky" parts of the tumor vasculature because of their small sizes, as well as from ultrasound-induced permeabilization of the tissue structure ([@bib0324]; [@bib0203]; [@bib0176]; [@bib0320]). Several research groups have reported tumor regression after treatment with acoustically active droplets ([@bib0108]; [@bib0281]; [@bib0041]; [@bib0176]) or gas-stabilizing solid particles ([@bib0198]; [@bib0203]). A different approach to the use of droplets for tumor treatment is ACT, which is based on microbubble-droplet clusters that upon ultrasound exposure, undergo a phase shift to create large bubbles that can transiently block capillaries ([@bib0262]). Although the mechanism behind the technique is not yet fully understood, studies have reported improved delivery and efficacy of paclitaxel and Abraxane in xenograft prostate tumor models ([@bib0281]; [@bib0150]). Another use of droplets for tumor treatment is enhanced high-intensity focused ultrasound (HIFU)-mediated heating of tumors ([@bib0146]).

Although microbubble-based drug delivery to solid tumors shows great promise, it also faces important challenges. The ultrasound parameters used in *in vivo* studies highly vary between research groups, and no consensus was found on the oscillation regime that is believed to be responsible for the observed effects ([@bib0288]; [@bib0261]). Moreover, longer ultrasound pulses and increased exposure times are usually applied in comparison to *in vitro* reports ([@bib0235]). This could promote additional effects such as microbubble clustering and microbubble translation, which could cause local damage to the surrounding tissue as well ([@bib0233]). To elucidate these effects further, fundamental *in vitro* research remains important. Therefore, novel *in vitro* models that more accurately mimic the complexity of the *in vivo* tumor environment are currently being explored. [@bib0218] engineered a perfusable vessel-on-a-chip system and reported successful doxorubicin delivery to the endothelial cells lining this microvascular network. While such microfluidic chips could be extremely useful to study the interactions of microbubbles with the endothelial cell barrier, special care of the material of the chambers should be taken to avoid ultrasound reflections and standing waves ([@bib0025]). Alternatively, 3-D tumor spheroids have been used to study the effects of ultrasound and microbubble-assisted drug delivery on penetration and therapeutic effect in a multicellular tumor model ([@bib0234]). Apart from expanding the knowledge on microbubble--tissue interactions in detailed parametric studies *in vitro*, it will be crucial to obtain improved control over the microbubble behavior *in vivo*, and link this to the therapeutic effects. To this end, passive cavitation detection to monitor microbubble cavitation behavior in real time is currently under development, and could provide better insights in the future ([@bib0053]; [@bib0104]; [@bib0112]). Efforts are being committed to construction of custom-built delivery systems, which can be equipped with multiple transducers allowing drug delivery guided by ultrasound imaging and/or passive cavitation detection ([@bib0080]; [@bib0053]; [@bib0287]; [@bib0216]).

Clinical studies {#sec0015}
----------------

### Pancreatic cancer {#sec0016}

The tolerability and therapeutic potential of improved chemotherapeutic drug delivery using microbubbles and ultrasound were first investigated for the treatment of inoperable pancreatic ductal adenocarcinoma at Haukeland University Hospital, Norway ([@bib0149]; [@bib0068]). In this clinical trial, gemcitabine was administered by intravenous injection over 30 min. During the last 10 min of chemotherapy, an abdominal echography was performed to locate the position of pancreatic tumor. At the end of chemotherapy, 0.5 mL of SonoVue microbubbles followed by 5 mL saline was intravenously injected every 3.5 min to ensure their presence throughout the whole sonoporation treatment. Pancreatic tumors were exposed to ultrasound (1.9 MHz, MI 0.2, 1% DC) using a 4C curvilinear probe (GE Healthcare) connected to an LOGIQ 9 clinical ultrasound scanner. The cumulative ultrasound exposure was only 18.9 s. All clinical data indicated that microbubble-mediated gemcitabine delivery did not induce any serious adverse events in comparison to chemotherapy alone. At the same time, tumor size and development were characterized according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. In addition, Eastern Cooperative Oncology Group performance status was used to monitor the therapeutic efficacy of microbubble-mediated gemcitabine delivery. All 10 patients tolerated an increased number of gemcitabine cycles compared with treatment with chemotherapy alone from historical controls (8.3 ± 6 vs. 13.8 ± 5.6 cycles, p \< 0.008), thus reflecting an improved physical state. After 12 treatment cycles, one patient\'s tumor exhibited a twofold decrease in tumor size. This patient was excluded from this clinical trial to be treated with radiotherapy and then with pancreatectomy. In 5 of the 10 patients, the maximum tumor diameter was partially decreased from the first to last therapeutic treatment. Subsequently, a consolidative radiotherapy or a FOLFIRINOX treatment, a bolus and infusion of 5-fluorouracil, leucovorin, irinotecan and oxaliplatin, was offered to them. The median survival was significantly increased from 8.9 to 17.6 mo (p = 0.0001). Together, these results indicate that drug delivery using clinically approved microbubbles, chemotherapeutics and ultrasound is feasible and compatible with respect to clinical procedures. Nevertheless, the authors did not provide any evidence that the improved therapeutic efficacy of gemcitabine was related to an increase in intra-tumoral bioavailability of the drug. In addition, the effects of microbubble-assisted ultrasound treatment alone on tumor growth were not investigated, while recent publications describe that according to the ultrasound parameters, such treatment could induce a significant decrease in tumor volume through a reduction in tumor perfusion as described above.

### Hepatic metastases from the digestive system {#sec0017}

A tolerability study of chemotherapeutic delivery using microbubble-assisted ultrasound for the treatment of liver metastases from gastrointestinal tumors and pancreatic carcinoma was conducted at Beijing Cancer Hospital, China ([@bib0289]). Thirty minutes after intravenous infusion of chemotherapy (for both monotherapy and combination therapy), 1 mL of SonoVue microbubbles was intravenously administered and was repeated another five times in 20 min. An ultrasound probe (C1-5 abdominal convex probe; GE Healthcare, USA) was positioned on the tumor lesion, which was exposed to ultrasound at different MIs (0.4--1) in contrast mode using a LogiQ E9 scanner (GE Healthcare, USA). The primary aims of this clinical trial were to evaluate the tolerability of this therapeutic procedure and to explore the largest MI and ultrasound treatment time that cancer patients can tolerate. According to the clinical tolerability evaluation, all 12 patients exhibited no serious adverse events. The authors reported that the microbubble-mediated chemotherapy led to fever in 2 patients. However, there is no clear evidence this is related to the microbubble and ultrasound treatment. Indeed, in the absence of direct comparison of these results with a historical group of patients receiving the chemotherapy on its own, one cannot rule out a direct link between the fever and the chemotherapy alone. All adverse side effects were resolved with symptomatic medication. In addition, the severity of side effects did not worsen with increases in MI, suggesting that microbubble-mediated chemotherapy is a tolerable procedure. The secondary aims were to assess the efficacy of this therapeutic protocol using contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI). Thus, tumor size and development were characterized according to the RECIST criteria. Half of the patients had stable disease, and one patient obtained a partial response after the first treatment cycle. The median progression-free survival was 91 d. However, comparison and interpretation of results are very difficult because none of the patients were treated with the same chemotherapeutics, MI and/or number of treatment cycles. The results of tolerability and efficacy evaluations should be compared with those for patients receiving the chemotherapy on its own to clearly identify the therapeutic benefit of combining therapy with ultrasound-driven microbubbles. Similar to the pancreatic clinical study, no direct evidence of enhanced therapeutic bioavailability of the chemotherapeutic drug after the treatment was provided. This investigation is all the more important as the ultrasound and microbubble treatment was applied 30 min after intravenous chemotherapy (for both monotherapy and combination therapy) independently of drug pharmacokinetics and metabolism.

### Ongoing and upcoming clinical trials {#sec0018}

Currently, two clinical trials are ongoing: (i) Professor F. Kiessling (RWTH Aachen University, Germany) proposes examining whether the exposure of early primary breast cancer to microbubble-assisted ultrasound during neoadjuvant chemotherapy results in increased tumor regression in comparison to that after ultrasound treatment alone (NCT03385200). (ii) Dr. J. Eisenbrey (Sidney Kimmel Cancer Center, Thomas Jefferson University, USA) is investigating the therapeutic potential of perflutren protein type A microspheres in combination with microbubble-assisted ultrasound in radioembolization therapy of liver cancer (NCT03199274).

A proof of concept study (NCT03458975) has been set in Tours Hospital, France, for treating non-resectable liver metastases. The aim of this trial is to perform a feasibility study with the development of a dedicated ultrasound imaging and delivery probe with a therapy protocol optimized for patients with hepatic metastases of colorectal cancer and who are eligible for monoclonal antibodies in combination with chemotherapy. A dedicated 1.5-D ultrasound probe has been developed and interconnected to a modified Aixplorer imaging platform (Supersonic Imagine, Aix-en-Provence, France). The primary objective of the study is to determine the rate of objective response at 2 mo for lesions receiving optimized and targeted delivery of systemic chemotherapy combining bevacizumab and FOLFIRI compared with those treated with only the systemic chemotherapy regimen. The secondary objective is to determine the tolerability of this local approach of optimized intra-tumoral drug delivery during the 3 mo of follow-up, by assessing tumor necrosis, tumor vascularity and pharmacokinetics of bevacizumab and by profiling cytokine expression spatially.

Immunotherapy {#sec0019}
=============

Cancer immunotherapy is considered to be one of the most promising strategies to eradicate cancer as it makes use of the patient\'s own immune system to selectively attack and destroy tumor cells. It is a common name that refers to a variety of strategies that aim to unleash the power of the immune system by either boosting antitumoral immune responses or flagging tumor cells to make them more visible to the immune system. The principle is that tumors express specific tumor antigens which are not expressed or expressed to a much lesser extent by normal somatic cells and hence can be used to initiate a cancer-specific immune response. In this section we aim to give insight into how microbubbles and ultrasound have been applied as useful tools to initiate or sustain different types of cancer immunotherapy, as illustrated in [Figure 3](#fig0003){ref-type="fig"}.Fig. 3Schematic overview of how microbubbles (MB) and ultrasound (US) have been found to contribute to cancer immunotherapy. From left to right: Microbubbles can be used as antigen carriers to stimulate antigen uptake by dendritic cells. Microbubbles and ultrasound can alter the permeability of tumors, thereby increasing the intra-tumoral penetration of adoptively transferred immune cells or checkpoint inhibitors. Finally, exposing tissues to cavitating microbubbles can induce sterile inflammation by the local release of damage-associated molecular patterns (DAMPS).Fig 3

When Ralph Steinman ([@bib0264]) discovered the dendritic cell (DC) in 1973, its central role in the initiation of immunity made it an attractive target to evoke specific antitumoral immune responses. Indeed, these cells very efficiently capture antigens and present them to T lymphocytes in major histocompatibility complexes (MHCs), thereby bridging the innate and adaptive immune systems. More specifically, exogenous antigens engulfed *via* the endolysosomal pathway are largely presented to CD4^+^ T cells *via* MHC-II, whereas endogenous, cytoplasmic proteins are shuttled to MHC-I molecules for presentation to CD8^+^ cells. As such, either CD4^+^ helper T cells or CD8^+^ cytotoxic T-cell responses are induced. The understanding of this pivotal role played by DCs formed the basis for DC-based vaccination, where a patient\'s DCs are isolated, modified *ex vivo* to present tumor antigens and re-administered as a cellular vaccine. DC-based therapeutics, however, suffer from a number of challenges, of which the expensive and lengthy *ex vivo* procedure for antigen loading and activation of DCs is the most prominent ([@bib0241]). In this regard, microbubbles have been investigated for direct delivery of tumor antigens to immune cells *in vivo*. [@bib0031] reported that intact microbubbles are rapidly phagocytosed by both murine and human DCs, resulting in rapid and efficient uptake of surface-coupled antigens without the use of ultrasound. Subcutaneous injection of microbubbles loaded with the model antigen ovalbumin (OVA) resulted in the activation of both CD8^+^ and CD4^+^ T cells. Effectively, these T-cell responses could partially protect vaccinated mice against an OVA-expressing *Listeria* infection. [@bib0066] investigated a different approach, making use of messenger RNA (mRNA)-loaded microbubbles combined with ultrasound to transfect DCs. As such, they were able to deliver mRNA encoding both tumor antigens and immunomodulating molecules directly to the cytoplasm of the DCs. As a result, preferential presentation of antigen fragments in MHC-I complexes was ensured, favoring the induction of CD8^+^ cytotoxic T cells. In a therapeutic vaccination study in mice bearing OVA-expressing tumors, injection of mRNA-sonoporated DCs caused a pronounced slowdown of tumor growth and induced complete tumor regression in 30% of the vaccinated animals. Interestingly, in humans, intradermally injected microbubbles have been used as sentinel lymph node detectors as they can easily drain from peripheral sites to the afferent lymph nodes ([@bib0245], [@bib0246]). As lymph nodes are the primary sites of immune induction, the interaction of microbubbles with intranodal DCs, could be of high value. To this end, [@bib0067] found that mRNA-loaded microbubbles were able to rapidly and efficiently migrate to the afferent lymph nodes after intradermal injection in healthy dogs. Unfortunately, further translation of this concept to an *in vivo* setting is not straightforward, as it prompts the use of less accessible large animal models (*e.g.,* pigs, dogs). Indeed, conversely to what has been reported in humans, lymphatic drainage of subcutaneously injected microbubbles is very limited in the small animal models typically used in pre-clinical research (mice and rats), which is the result of substantial differences in lymphatic physiology.

Another strategy in cancer immunotherapy is adoptive cell therapy, in which *ex vivo* manipulated immune effector cells, mainly T cells and natural killer (NK) cells, are employed to generate a robust and selective anticancer immune response ([@bib0308]; [@bib0124]). These strategies have mainly led to successes in hematological malignancies, not only because of the availability of selective target antigens, but also because of the accessibility of the malignant cells ([@bib0138]; [@bib0308]). By contrast, in solid tumors, and especially in brain cancers, inadequate homing of cytotoxic T cells or NK cells to the tumor proved to be one of the main reasons for the low success rates, making the degree of tumor infiltration an important factor in disease prognosis ([@bib0051]; [@bib0105]; [@bib0308]). To address this, focused ultrasound and microbubbles have been used to make tumors more accessible to cellular therapies. The first demonstration of this concept was provided by [@bib0007], who used a xenograft HER-2-expressing breast cancer brain metastasis model to determine whether ultrasound and microbubbles could allow intravenously infused NK cells to cross the BBB. By loading the NK cells with superparamagnetic iron oxide nanoparticles, the accumulation of NK cells in the brain could be tracked and quantified *via* MRI. An enhanced accumulation of NK cells was found when the cells were injected immediately before BBB disruption. Importantly NK cells retained their activity and ultrasound treatment resulted in a sufficient NK-to-tumor cell ratio to allow effective tumor cell killing ([@bib0008]). In contrast, very few NK cells reached the tumor site when BBB disruption was absent or performed before NK cell infusion. Although it is not known for certain why timing had such a significant impact on NK extravasation, it is likely that the most effective transfer to the tissue occurs at the time of insonification, and that the barrier is most open during this time ([@bib0185]). Possible other explanations include the difference in size of the temporal BBB openings or a possible alternation in the expression of specific leukocyte adhesion molecules by the BBB disruption, thus facilitating the translocation of NK cells. Also, for tumors where BBB crossing is not an issue, ultrasound has been used to improve delivery of cellular therapeutics. [@bib0263] reported enhanced tumor infiltration of adoptively transferred NK cells after treatment with microbubbles and low-dose focused ultrasound. This result was confirmed by [@bib0305] in a more recent publication where the homing of NK cells more than doubled after microbubble injection and ultrasound treatment of an ovarian tumor. Despite the enhanced accumulation, however, the authors did not observe an improved therapeutic effect, which might be owing to the limited number of treatments that were applied or the immunosuppressive tumor microenvironment that counteracts the cytotoxic action of the NK cells.

There is growing interest in exploring the effect of microbubbles and ultrasound on the tumor microenvironment, as recent work has indicated that BBB disruption with microbubbles and ultrasound may induce sterile inflammation. Although a strong inflammatory response may be detrimental in the case of drug delivery across the BBB, it might be interesting to further study this inflammatory response in solid tumors as it might induce the release of damage-associated molecular patterns (DAMPS) such as heat-shock proteins and inflammatory cytokines. This could shift the balance toward a more inflammatory microenvironment that could promote immunotherapeutic approaches. As reported by [@bib0173] exposure of a CT26 colon carcinoma xenograft to microbubbles and low-pressure pulsed ultrasound increased cytokine release and triggered lymphocyte infiltration. Similar data have been reported by [@bib0126]. In their study, ultrasound treatment caused a complete shutdown of tumor vasculature followed by the expression of hypoxia-inducible factor 1α (HIF-1α), a marker of tumor ischemia and tumor necrosis, as well as increased infiltration of T cells. Similar responses have been reported after thermal and mechanical HIFU treatments of solid tumors ([@bib0278]; [@bib0259]). A detailed review of ablative ultrasound therapies is, however, out of the scope of this review.

At present, the most successful form of immunotherapy is the administration of monoclonal antibodies to inhibit regulatory immune checkpoints that block T-cell action. Examples are cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1), which act as brakes on the immune system. Blocking the effect of these brakes can revive and support the function of immune effector cells. Despite the numerous successes achieved with checkpoint inhibitors, responses have been quite heterogeneous as the success of checkpoint inhibition therapy depends largely on the presence of intra-tumoral effector T cells ([@bib0291]). This motivated [@bib0034] to explore the synergy of microbubble and ultrasound treatment with PD-L1 checkpoint inhibition therapy in mice. Tumors in the treatment group that received the combination of microbubble and ultrasound treatment with checkpoint inhibition were significantly smaller than tumors in the monotherapy groups. One mouse exhibited complete tumor regression and remained tumor free upon rechallenge, indicative of an adaptive immune response.

Overall, the number of studies that have investigated the impact of microbubble and ultrasound treatment on immunotherapy is limited, making this a rather unexplored research area. It is obvious that more in-depth research is warranted to improve our understanding on how (various types of) immunotherapy might benefit from (various types of) ultrasound treatment.

BBB and blood--spinal cord barrier opening {#sec0020}
==========================================

The barriers of the central nervous system (CNS), the BBB and blood--spinal cord barrier (BSCB), greatly limit drug-based treatment of CNS disorders. These barriers help to regulate the specialized CNS environment by limiting the passage of most therapeutically relevant molecules ([@bib0215]). Although several methods have been proposed to circumvent the BBB and BSCB, including chemical disruption and the development of molecules engineered to capitalize on receptor-mediated transport (so-called Trojan horse molecules), the use of ultrasound in combination with microbubbles ([@bib0127]) or droplets ([@bib0298]) to transiently modulate these barriers has come to the forefront in recent years because of the targeted nature of this approach and its ability to facilitate delivery of a wide range of currently available therapeutics. First demonstrated in 2001 ([@bib0127]), ultrasound-mediated BBB opening has been the topic of several hundred original research articles in the last two decades and, in recent years, has made headlines for groundbreaking clinical trials targeting brain tumors and Alzheimer\'s disease as described later under Clinical Studies.

Mechanisms, bio-effects and tolerability {#sec0021}
----------------------------------------

Ultrasound in combination with microbubbles can produce permeability changes in the BBB *via* both enhanced paracellular and transcellular transport ([@bib0249], [@bib0250]). Reduction and reorganization of tight junction proteins ([@bib0251]) and upregulation of active transport protein caveolin-1 ([@bib0063]) have been reported. Although the exact physical mechanisms driving these changes are not known, there are several factors that are hypothesized to contribute to these effects, including direct tensile stresses caused by the expansion and contraction of the bubbles in the lumen, as well as shear stresses at the vessel wall arising from acoustic microstreaming. Recent studies have also investigated the suppression of efflux transporters after ultrasound exposure with microbubbles. A reduction in P-glycoprotein expression ([@bib0052]; [@bib0015]) and BBB transporter gene expression ([@bib0194]) has been observed by multiple groups. One study found that P-glycoprotein expression was suppressed for more than 48 h after treatment with ultrasound and microbubbles ([@bib0015]). However, the degree of inhibition of efflux transporters as a result of ultrasound with microbubbles may be insufficient to prevent efflux of some therapeutics ([@bib0102]), and thus this mechanism requires further study.

Many studies have documented enhanced CNS tumor response after ultrasound and microbubble-mediated delivery of drugs across the blood--tumor barrier in rodent models. Improved survival has been observed in both primary ([@bib0045]; [@bib0014]) and metastatic ([@bib0217]; [@bib0008]) tumor models.

Beyond simply enhancing drug accumulation in the CNS, several positive bio-effects of ultrasound and microbubble-induced BBB opening have been reported. In rodent models of Alzheimer\'s disease, numerous positive effects have been discovered in the absence of exogenous therapeutics. These effects include a reduction in amyloid-β plaque load ([@bib0133]; [@bib0037]; [@bib0164]; [@bib0223]), reduction in tau pathology ([@bib0214]) and improvements in spatial memory ([@bib0037]; [@bib0164]). Two-photon microscopy has revealed that amyloid-β plaque size is reduced in transgenic mice for up to 2 wk after ultrasound and microbubble treatment ([@bib0223]). Opening of the BBB in both transgenic and wild-type mice has also revealed enhanced neurogenesis ([@bib0037]; [@bib0242]; [@bib0202]) in the treated tissue.

Gene delivery to the CNS using ultrasound and microbubbles is another area that is increasingly being investigated. Viral ([@bib0009]; [@bib0286]) and non-viral ([@bib0195]) delivery methods have been investigated. While early studies reported the feasibility of gene delivery using reporter genes (*e.g.,* [@bib0273]; [@bib0009]), there have been promising results delivering therapeutic genes. In particular, advances have been made in Parkinson\'s disease models, where therapeutic genes have been tested ([@bib0196]; [@bib0299]) and where long-lasting functional improvements have been reported in response to therapy ([@bib0196]). It is expected that research into this highly promising technique will expand to a range of therapeutic applications.

Despite excellent tolerability profiles in non-human primate studies investigating repeat opening of the BBB ([@bib0190]; [@bib0074]), there has been recent controversy because of reports of a sterile inflammatory response observed in rats ([@bib0151], [@bib0152]; [@bib0258]). The inflammatory response is proportional to the magnitude of BBB opening and is therefore strongly influenced by experimental conditions such as microbubble dose and acoustic settings. However, [@bib0193] reported that when clinical microbubble doses are used, and treatment exposures are actively controlled to avoid overtreating, the inflammatory response is acute and mild. They note that while chronic inflammation is undesirable, acute inflammation may actually contribute to some of the positive bio-effects that have been observed. For example, the clearance of amyloid-β after ultrasound and microbubble treatment is thought to be mediated in part by microglial activation ([@bib0133]). These findings reiterate the need for carefully controlled treatment exposures to select for desired bio-effects.

Cavitation monitoring and control {#sec0022}
---------------------------------

It is generally accepted that the behavior of the microbubbles in the ultrasound field is predictive, to an extent, of the observed bio-effects. In the seminal study on the association between cavitation and BBB opening, [@bib0189] observed an increase in second harmonic emissions in cases of successful opening, compared with exposures that led to no observable changes in permeability as measured by contrast-enhanced MRI. Further, they noted that successful opening could be achieved in the absence of inertial cavitation, which was also reported by another group ([@bib0277]). These general guidelines have been central to the development of active treatment control schemes that have been developed to date---all with the common goal of promoting stable bubble oscillations, while avoiding violent bubble collapse that can lead to tissue damage. These methods are based either on detection of sub- or ultraharmonic ([@bib0209]; [@bib0276]; [@bib0030]), harmonic bubble emissions ([@bib0012]; [@bib0268]) or a combination thereof ([@bib0136]). An approach based on the sub-/ultraharmonic controller developed by [@bib0209] has been employed in early clinical testing ([@bib0172]; [@bib0182]).

Control methods presented to date have generally been developed using single receiver elements, which simplifies data processing but does not allow signals to be localized. Focused receivers are spatially selective but can miss off-target events, while planar receivers may generate false positives based on signals originating outside the treatment volume. The solution to this is to use an array of receivers and passive beamforming methods, combined with phase correction methods to compensate for the skull bone ([@bib0130], [@bib0131]), to generate maps of bubble activity. In the brain this has been achieved with linear arrays ([@bib0013]; [@bib0307]), which suffer from poor axial resolution when using passive imaging methods, as well as large-scale sparse hemispherical or large aperture receiver arrays ([@bib0210]; [@bib0065]; [@bib0055]; [@bib0132]; [@bib0175]) that optimize spatial resolution for a given frequency. Recently, this has extended beyond just imaging the bubble activity to incorporate real-time, active feedback control based on both the spectral and spatial information obtained from the bubble maps ([@bib0132]) ([Fig. 4](#fig0004){ref-type="fig"}). Robust control methods building on these works will be essential for widespread adoption of this technology to ensure tolerable and consistent treatments.Fig. 4Three-dimensional transcranial subharmonic microbubble imaging and treatment control *in vivo* in rabbit brain during blood--brain barrier opening. Spectral information (top) indicates the appearance of subharmonic activity at *t* = 35 s into the treatment. Passive mapping of the subharmonic band localizes this activity to the target region. Bar = 2.5 mm. Reprinted (adapted), with permission, from [@bib0132].Fig 4

BSCB opening {#sec0023}
------------

Despite the similarities between the BBB and BSCB, and the great potential benefit for patients, there has been limited work investigating translation of this technology to the spinal cord. Opening of the BSCB in rats was first reported by [@bib0284], and was followed by studies from [@bib0290], [@bib0219] and [@bib0211] in rats ([Fig. 5](#fig0005){ref-type="fig"}) and from [@bib0201] in rabbits, the latter performed through a laminectomy window. In 2018, [@bib0211] presented the first evidence of a therapeutic benefit in a disease model, showing improved tumor control in a rat model of leptomeningeal metastases.Fig. 5T~1~-Weighted sagittal magnetic resonance images revealing leptomeningeal tumors in rat spinal cord (*gray arrowhead*) before ultrasound and microbubble treatment (left column), and the enhancement of the cord indicating blood--spinal cord barrier opening (*white arrows*) after ultrasound and microbubble treatment (right column). Reprinted (adapted) with permission from [@bib0211].Fig 5

Although promising, significant work remains to be done to advance BSCB opening to clinical studies. A more thorough characterization of the bio-effects in the spinal cord and how, if at all, they differ from those in the brain is necessary to ensure safe translation. Additionally, methods and devices capable of delivering controlled therapy to the spinal cord at clinical scale are needed. While laminectomy and implantation of an ultrasound device ([@bib0201]) might be an appropriate approach for some focal indications, treating multifocal or diffuse disease will require the ultrasound to be delivered through the intact bone to the narrow spinal canal. [@bib0088] have described a method to suppress standing waves in the human vertebral canal. Combined with devices suited to the spinal geometry, such as that presented by [@bib0302], these methods will help to advance clinical translation.

Clinical studies {#sec0024}
----------------

The feasibility of enhancing BBB permeability in and around brain tumors using ultrasound and microbubbles has now been tested in two clinical trials. In the study conducted at Assistance Publique-Hôpitaux de Paris in Paris, France, an unfocused 1-MHz ultrasound transducer (SonoCloud) was surgically placed over the tumor resection area and permanently fixed into the hole in the skull bone. The skin was placed over the transducer, and after healing, treatments were conducted by inserting a needle probe through the skin to provide the driving signal to the transducer. Monthly treatments were then conducted while infusing a chemotherapeutic agent into the bloodstream (carboplatin). The sonication was executed during infusion of SonoVue microbubbles. A constant pulsed sonication was applied during each treatment, followed by a contrast-enhanced MRI to estimate BBB permeability. The power was escalated for each monthly treatment until enhancement was detected on MRI. This study reported the feasibility and tolerability ([@bib0042]), and a follow-up study may indicate increase in survival ([@bib0128]).

The second brain tumor study was conducted at Sunnybrook Health Sciences Centre in Toronto, Canada, which used the InSightec Exablate 220 kHz device and through-skull MRI-guided sonications of brain tumors before the surgical resection. It also described the feasibility of inducing highly localized BBB permeability enhancement and tolerability, and reported that chemotherapeutic concentration in the sonicated peritumor tissue was higher than in the unsonicated tissue ([@bib0182]).

Another study conducted in Alzheimer\'s disease patients with the Exablate device reported tolerable BBB permeability enhancement and that the treatment could be repeated 1 mo later without any imaging or behavior indications of adverse events ([@bib0172]). A third study with the same device investigated the feasibility of using functional MRI to target motor cortex in amyotrophic lateral sclerosis patients, again finding precisely targeted BBB permeability enhancement without adverse effects in this delicate structure ([@bib0001]). All of these studies were conducted using Definity microbubbles. These studies have led to the current ongoing brain tumor trial with six monthly treatments of the brain tissue surrounding the resection cavity during the maintenance phase of the treatment with temozolomide. This study sponsored by InSightec is being conducted in multiple institutions. Similarly, a phase II trial in Alzheimer\'s disease sonicating the hippocampus with the goal of investigating the tolerability and potential benefits from repeated (three treatments with 2-wk interval) BBB permeability enhancement alone is ongoing. This study is also being conducted in several institutions that have the device.

Sonothrombolysis {#sec0025}
================

Occlusion of blood flow through diseased vasculature is caused by thrombi, blood clots that form in the body. Because of limitations in thrombolytic efficacy and speed, sonothrombolysis, ultrasound which accelerates thrombus breakdown alone, or in combination with thrombolytic drugs and/or cavitation nuclei, has been under extensive investigation in the last two decades ([@bib0020]). Sonothrombolysis promotes thrombus dissolution for the treatment of stroke ([@bib0005], [@bib0006]; [@bib0199]; [@bib0050]), myocardial infarction ([@bib0186], [@bib0187]; [@bib0260]), acute peripheral arterial occlusion ([@bib0076]), deep vein thrombosis (DVT) ([@bib0255]) and pulmonary embolism ([@bib0075]; [@bib0079]; [@bib0163]).

Mechanisms, agents and approaches {#sec0026}
---------------------------------

Ultrasound improves recombinant tissue plasminogen activator (rt-PA) diffusion into thrombi and augments lysis primarily *via* acoustic radiation force and streaming ([@bib0057]; [@bib0225]; [@bib0221]). Additionally, ultrasound increases rt-PA and plasminogen penetration into the thrombus surface and enhances removal of fibrin degradation products *via* ultrasonic bubble activity, or acoustic cavitation, which induces microstreaming ([@bib0078]; [@bib0057]; [@bib0269]). Two types of cavitation are correlated with enhanced thrombolysis: stable cavitation, with highly non-linear bubble motion resulting in acoustic emissions at the subharmonic and ultraharmonics of the fundamental frequency ([@bib0091]; [@bib0222]; [@bib0018]), and inertial cavitation, with substantial radial bubble growth and rapid collapse generating broadband acoustic emissions ([@bib0043]; [@bib0094]).

Specialized contrast agents and tailored ultrasound schemes have been investigated with the aim of optimizing sonothrombolysis. [@bib0221] observed a greater degree of rt-PA lysis with BR38 microbubbles exposed to 1 MHz pulsed ultrasound at an amplitude causing inertial cavitation (1.3 MPa peak rarefactional pressure) than at a lower amplitude causing stable cavitation (0.35 MPa peak rarefactional pressure). [@bib0103] also measured a higher degree of thrombolysis with 1 MHz pulsed ultrasound at 1.0 MPa peak rarefactional pressure with inertial cavitation than at 0.23 MPa peak rarefactional pressure with stable cavitation in an *in vitro* model of microvascular obstruction using perfluorobutane-filled, lipid-shelled microbubbles ([@bib0294]) as a nucleation agent. However, [@bib0142] observed more than 60% fractional clot width loss for highly retracted human whole blood clots exposed to rt-PA, Definity and 220 kHz pulsed or continuous wave (CW) ultrasound at an acoustic output with sustained stable cavitation throughout the insonification periods (0.22 MPa peak rarefactional pressure) ([Fig. 6](#fig0006){ref-type="fig"}).Fig. 6Simulated acoustic pressure and temperature in a representative subject exposed to pulsed 220 kHz ultrasound with a 33.3% duty cycle. The absolute peak-to-peak pressure maximum for the simulations is displayed in gray scale. Temperature is displayed using a heat map with a minimum color priority write threshold of 1°C. Computed tomography features such as bone (*cyan*), skin and internal epithelium (*beige*) and clot (*green*) are plotted using contour lines. The transducer is outlined in *magenta*. Constructive interference is prominent in the soft tissue between the temporal bone and the transducer. Some constructive interference is also present in the brain tissue close to the contralateral temporal bone; however, the pressure in this region did not exceed the pressure in the M1 section of the middle cerebral artery. Temperature rise was prominent in the ipsilateral bone along the transducer axis. The computational model is described in [@bib0142].Fig 6

Echogenic liposomes loaded with rt-PA enhanced lysis compared with rt-PA alone at concentrations of 1.58 and 3.15 mg/mL ([@bib0252]), suggesting that encapsulation of rt-PA could reduce the rt-PA dose by a factor of 2 with equivalent lytic activity. Subsequently it has been found that these liposomes protect rt-PA against degradation by plasminogen activator inhibitor 1, while achieving equivalent thrombolytic efficacy relative to rt-PA, Definity and intermittent 220 kHz CW ultrasound ([@bib0253]). Promising agents, including a nanoscale (\<100 nm) contrast agent ([@bib0033]) and magnetically targeted microbubbles ([@bib0060]), have also exhibited enhanced rt-PA thrombolysis *in vitro*. All of these investigators noted that in the absence of rt-PA, the combination of ultrasound and microbubbles did not degrade the fibrin network.

Several minimally invasive techniques have also been explored, with or without the inclusion of rt-PA or exogenous cavitation nuclei. In the clinical management of stroke, rapid treatments are needed because of the neurologist\'s adage "time is brain." Thus, treatment options that promote fast clot removal, reduce edema and intracerebral bleeding and improve patient outcomes are of immense value. Magnetic resonance image-guided HIFU has been investigated for the treatment of both ischemic ([@bib0036]) and hemorrhagic ([@bib0200]) stroke, and [@bib0316] have provided an excellent review of the literature for this approach. Histotripsy, a form of HIFU that relies on the mechanical action of microbubble clouds to ablate thrombi with and without rt-PA ([@bib0188]; [@bib0019], [@bib0021]; [@bib0319]) is under development to treat deep vein thrombosis. Additionally, ultrasound-accelerated catheter-directed thrombolysis using the EKOS system (EKOS/BTG, Bothell, WA, USA) combines 2 MHz low-intensity pulsed ultrasound and rt-PA without cavitation nuclei to improve lytic efficiency to treat DVT ([@bib0255]) and pulmonary embolism ([@bib0098]).

Cavitation monitoring {#sec0027}
---------------------

Acoustic cavitation has been reported to mediate direct fibrinolysis ([@bib0293]) and accelerated rt-PA lysis ([@bib0081]; [@bib0057]; [@bib0225]; [@bib0116]). Passive and active cavitation detection techniques have been developed to monitor acoustic cavitation ([@bib0239]; [@bib0180]; [@bib0019]). Passive cavitation imaging, or passive acoustic mapping, employs a transducer array that listens passively (*i.e.,* no transmit) to emissions from acoustically activated microbubbles ([@bib0240]; [@bib0109]; [@bib0112]). [@bib0282] developed a prototype array enabling spectral analysis of bubble activity for sonothrombolysis applications. Superharmonic Doppler effects have also been utilized to monitor bubble activity from 500 kHz pulsed therapeutic ultrasound ([@bib0224]). Both a linear array ([@bib0010], [@bib0011]; [@bib0013]) and a sparse hemispherical array ([@bib0003]) have been integrated into a clinical magnetic resonance image-guided HIFU system to assess microbubble dynamics during sonothrombolysis in the brain.

Pre-clinical studies {#sec0028}
--------------------

Information gathered from animal studies can help inform human clinical trials, despite a strong species dependence of clot rt-PA lytic susceptibility ([@bib0097]; [@bib0089]; [@bib0125]). A comprehensive systematic evaluation of 16 *in vivo* pre-clinical sonothrombolysis studies was carried out by [@bib0016] summarizing treatment efficacy and tolerability outcomes in models of ischemic stroke. Since that review was published, the efficacy of sonothrombolysis using nitrogen microbubbles stabilized with a non-cross-linked shell delivered intra-arterially through a catheter and rt-PA delivered intravenously has been explored in a rat model of ischemic stroke ([@bib0069]).

Clinical studies {#sec0029}
----------------

There exists a rich literature on clinical trials exploring the tolerability and efficacy of sonothrombolysis. Two recent meta-analyses of seven randomly assigned controlled trials ([@bib0050]; [@bib0316]) attempt to determine whether the administration of rt-PA and ultrasound improves outcomes in acute ischemic stroke. Both analyses conclude that sonothrombolysis significantly enhances complete or partial recanalization, with improved neurologic function (assessed *via* the National Institutes of Health Stroke Scale). An ongoing clinical trial (Aureva Transcranial Ultrasound Device With tPA in Patients With Acute Ischemic Stroke (TRUST), NCT03519737) will determine whether large vessel occlusions can be re-canalized with sonothrombolysis (Cerevast Medical, Inc., Bothell, WA, USA) and rt-PA, tenecteplase or alteplase ([@bib0039]), while patients are transferred to a stroke center for mechanical thrombectomy ([@bib0099]).

Several clinical trials have indicated that high-MI pulsed diagnostic ultrasound exposure of Definity before and after percutaneous coronary intervention for ST elevation myocardial infarction can prevent microvascular obstruction and improve functional outcomes ([@bib0186], [@bib0187]; [@bib0260]). A systematic review of 16 catheter-directed sonothrombolysis clinical trials composed mostly of retrospective case series using the EKOS system without microbubble infusions determined that this treatment modality is tolerable and promising for the treatment of DVT ([@bib0255]). However, a large-sample randomly assigned prospective clinical trial is needed to improve the clinical evidence for use as a front-line therapy for DVT. In retrospective studies in patients with pulmonary embolism, [@bib0163] conclude that catheter-directed sonothrombolysis is tolerable and decreases right-sided heart strain, but [@bib0243] conclude that this therapy is not associated with a reduction in mortality or increased resolution of right ventricular dysfunction. And finally, an ongoing trial in a small cohort of 20 patients with acute peripheral arterial occlusions ([@bib0076]) will determine whether Luminity (marketed in the United States as Definity) and 1.8 MHz transdermal diagnostic ultrasound with intermittent high MI (1.08) and low MI (0.11) for visualization of the microbubbles and flow will improve recanalization. In summary, sonothrombolysis has been found to have clinical benefit in the treatment of acute and chronic thrombotic disease. Ultrasound-assisted thrombolysis has a potential role as an emerging viable and therapeutic option for future management of stroke and cardiovascular disease.

Cardiovascular drug delivery and therapy {#sec0030}
========================================

In cardiovascular drug delivery, cavitation nuclei are co-administered or loaded with different therapeutics for the treatment of various diseases. For atherosclerosis treatment in an ApoE-deficient mouse model, intercellular adhesion molecule-1-targeted microbubbles carrying the angiogenesis inhibitor Endostar were used ([@bib0314]). Upon intermittent insonification over the abdominal and thoracic cavity with 1 MHz ultrasound (2 W/cm^2^ intensity, 50% duty cycle) for 30 s with two repeats and another treatment 48 h later, plaque area and intraplaque neovascularization were significantly reduced 2 wk after treatment. Percutaneous coronary intervention is often used to restore blood flow in atherosclerotic arteries. The treatment of coronary microembolization, a complication of percutaneous coronary intervention, was demonstrated in pigs treated with ultrasound (1 MHz, 2.0 W/cm^2^ intensity, 10 s on and 10 s off, 20-min duration) and microRNA-21-loaded microbubbles 4 d before coronary microembolization ([@bib0266]). This resulted in an improved cardiac dysfunction. Although not a therapeutic study, [@bib0174] did find that plasmid transfection to the myocardium was significantly larger when the microbubbles were administered into the coronary artery compared with intravenously *via* the ear vein in pigs even though the intracoronary microbubble dose was half of the intravenous dose (1 MHz ultrasound, 2 W/cm^2^, 50% duty cycle, 20-min duration). Percutaneous coronary intervention can also result in neointimal formation, which induces restenosis. Sirolimus-loaded microbubbles were found to reduce neointimal formation in coronary arteries by 50% in pigs (see [Fig. 7](#fig0007){ref-type="fig"}), 28 d after angioplasty in combination with a mechanically rotating intravascular ultrasound catheter (5 MHz, 500 cycles, 50% duty cycle, 0.6-MPa peak negative pressure) ([@bib0140]). Another research group reported that paclitaxel-loaded microbubbles and ultrasound (1 MHz, 1.5 MPa for 10 s) can also significantly inhibit neointimal formation in the iliac artery in rabbits 1 wk after percutaneous coronary intervention ([@bib0328]).Fig. 7Histologic sections of a coronary artery of a pig 28 d after angioplasty. Pigs were treated with sirolimus-loaded microbubbles only (a) or sirolimus-loaded microbubbles and ultrasound (b) using a mechanically rotating intravascular ultrasound catheter (5 MHz, 500 cycles, 50% duty cycle, 0.6 MPa peak negative pressure). Treatment with ultrasound and sirolimus-loaded microbubbles reduced neointimal formation by 50%. In both sections, the intima (I) and media (M) are outlined. Bar = 500 µm. Reprinted with permission from Springer Nature: Springer, Annals of Biomedical Engineering, Reducing Neointima Formation in a Swine Model with IVUS and Sirolimus Microbubbles, Kilroy JP, Dhanaliwala AH, Klibanov AL, Bowles DK, Wamhoff BR, Hossack JA, COPYRIGHT, from [@bib0140].Fig 7

In diabetic cardiomyopathy, microbubble-mediated delivery of fibroblast growth factor has shown therapeutic effects. [@bib0323] could prevent diabetic cardiomyopathy in rats by treating the heart with ultrasound (14 MHz, 7.1 MPa for 10 s, three repeats with off interval of 1 s) and microbubbles co-administered with acidic fibroblast growth factor nanoparticles twice weekly for 12 consecutive wk. In already established diabetic cardiomyopathy in rats, the same investigators co-administered basic fibroblast growth factor-containing nanoparticles with microbubbles with the same ultrasound treatment, albeit that it was given three times with 1 d in between treatments. At 4 wk after treatment, this resulted in restored cardiac function as a result of structural remodeling of the cardiac tissue ([@bib0322]). Microbubbles loaded with acidic fibroblast growth factor in combination with ultrasound (14 MHz, 7.1 MPa for 10 s, three repeats with off interval of 1 s) also resulted in significantly improved cardiac function in a rat model of diabetic cardiomyopathy. Treatment was performed twice weekly for 12 consecutive wk ([@bib0318]). For doxorubicin-induced cardiomyopathy, repeated co-administration of microbubbles and nanoparticles containing acidic fibroblast growth factor in combination with ultrasound (14 MHz, 7.1 MPa for 10 s, three repeats with off interval of 1 s) applied at the heart successfully prevented doxorubicin-induced cardiomyopathy in rats ([@bib0274]). Once doxorubicin-induced cardiomyopathy had occurred, microbubble-mediated reversal of cardiomyopathy was shown by the delivery of surviving plasmid to cardiomyocytes and endothelial cells ([@bib0162]) or glucagon-like peptide-1 to cardiomyocytes, endothelial cells, vascular muscle cells and mesenchymal cells ([@bib0048]) in rats. The ultrasound settings were 5 MHz (120 V power, pulsing interval of 10 cardiac cycles at end-systole) for a 5 min treatment ([@bib0162]) or not specified ([@bib0048]). The microbubble-mediated gene therapy study by [@bib0049] indicated that ANGPTL8 gene therapy does not need to be done in the heart to reverse doxorubicin-induced cardiomyopathy in rats as their microbubble and ultrasound (1.3 MHz, 1.4 MPa peak negative pressure, four bursts triggered to every fourth end-systole using a delay of 45--70 ms of the peak of the R wave) therapy was done in the liver (90 s treatment). This resulted in overexpression of ANGPTL8 in liver cells and blood, which stimulated cardiac progenitor cells in the epicardium.

A few dozen articles have been published on treating myocardial infarction with microbubble and ultrasound-mediated gene delivery *in vivo*, in mouse, rat, rabbit and dog models. These are reviewed by [@bib0227]. Amongst these are a few targeted microbubble studies which all indicate that the targeted microbubbles induced higher degrees of gene transfection, increased myocardial vascular density and improved cardiac function in comparison to non-targeted microbubbles. This improvement occurred independent of the type of ligand on the microbubble, the gene that was transfected or the animal model: matrix metalloproteinase 2 target with Timp3 gene in rats ([@bib0304]), intracellular adhesion molecule-1 target with Ang-1 gene in rabbits ([@bib0064]), P-selectin target with hVEGF165 gene in rats ([@bib0254]). Ultrasound settings for these studies were similar at 1.6 MHz (1.6 MPa peak negative pressure, pulsing interval of 4 cardiac cycles) for 20 min during infusion of the plasmid-loaded microbubbles (both [@bib0304] and [@bib0254]) or 1.7 MHz (1.7 MPa peak negative pressure, pulsing interval every 4--8 cardiac cycles) for 5 min after bolus injection of the plasmid-loaded microbubbles ([@bib0064]).

Other gene therapy studies for vascular disease include stimulating angiogenesis for the treatment of chronic hindlimb ischemia in rats using miR-126-3p-loaded microbubbles and ultrasound (1.3 MHz, 2.1 MPa peak negative acoustic pressure, pulsing interval 5 s). The treatment lasted 20 min during which microbubbles were infused for 10 min and resulted in improved perfusion, vessel density, arteriolar formation and neovessel maturation ([@bib0040]). Recently, successful gene therapy was reported in baboons in which vascular endothelial growth factor (VEGF)-plasmid loaded microbubbles were infused and ultrasound (2--6 MHz, MI 1.9, repeated 5 s burst pulses with three bursts per min) was applied for 10 min on days 25, 35, 45 and 55 of gestation, with the transducer placed over the placental basal plate ([@bib0017]). This was a mechanistic study elucidating the role of VEGF in uterine artery remodeling.

The gas core of the cavitation nuclei can also be the therapeutic. [@bib0270] have found that ultrasound-mediated (1 MHz, 0.34 MPa acoustic pressure, 30 cycle pulse, 50 s treatment) nitric oxide gas delivery from echogenic liposomes to *ex vivo*-perfused porcine carotid arteries induces potent vasorelaxation. The vasodilative effect of nitric oxide-loaded echogenic liposomes upon insonification (5.7 MHz, 0.36 MPa peak negative pressure, 30 s treatment) was also shown in *ex vivo* perfused rabbit carotid arteries with arterial wall penetration of nitric oxide confirmed by fluorescence microscopy ([@bib0141]). In addition to this, vasodilative effects were reported in carotid arteries *in vivo* in rats with vasospasms after subarachnoid hemorrhage using 1 MHz ultrasound with 0.3 MPa peak-to-peak pressure, 50% duty cycle for a duration of 40 min with constant infusion of the echogenic liposomes. This resulted in improved neurologic function (limb placement, beam and grid walking) ([@bib0141]). Ultrasound activation of the antioxidant hydrogen gas encapsulated in microbubbles was reported to prevent myocardial ischemia--reperfusion injury in rats when administered before reperfusion ([@bib0113]). There was a dose-dependent effect as 2 × 10^10^ microbubbles resulted in a more significant reduction in infarct size (70%) than 4 × 10^9^ microbubbles (39%) compared with vehicle-treated rats. Furthermore, treatment with the high-dose hydrogen microbubbles prevented changes in left ventricular end-diastolic and left ventricular end-systolic dimensions, as well as minimal reductions in ejection fraction and fractional shortening. Histologic and ELISA analyses revealed a reduced degree of myocardial necrosis, apoptosis, hemorrhaging, inflammation and oxidant damage. At the same time that cardiovascular drug delivery and therapy using microbubbles and ultrasound is moving forward to large animal and clinical studies, sophisticated *in vitro* models are being used and/or developed for mechanistic studies, such as flow chambers (µSlides, Ibidi) ([@bib0247]) and perfused 3-D microvascular networks ([@bib0134]), in which human umbilical vein endothelial cells are grown.

Clinical study {#sec0031}
--------------

Microbubbles and ultrasound were clinically investigated to augment muscle blood flow in 12 patients with stable sickle cell disease in the absence of a drug at the Oregon Health & Science University, Portland, Oregon, USA ([@bib0028]). Perfusion increased ∼2-fold in the forearm flexor muscles upon Definity infusion and insonification at 1.3 MHz (MI 1.3). Ultrasound was applied three times for 3 min with ∼5 min intervals. The change in perfusion was determined from contrast-enhanced ultrasound imaging and extended well beyond the region where ultrasound was applied. This study indicated that the therapeutic ultrasound settings directly translate from mouse to human for superficial muscles, as the same investigators found augmented blood flow in ischemic and non-ischemic hindlimb muscles in mice in the same study and an earlier publication ([@bib0027]). However, for the pre-clinical studies, custom-made microbubbles were used instead of Definity.

Sonobactericide {#sec0032}
===============

Sonobactericide has been defined as the use of ultrasound in the presence of cavitation nuclei for the enhancement of bactericidal action ([@bib0158]). This topic has recently gained attention, with 17 papers being published in the last 5 y. Research on ultrasound-mediated enhancement of antimicrobials has focused on several sources of infections including general medical devices ([@bib0232]; [@bib0072], [@bib0073]; [@bib0123]; [@bib0096]), acne ([@bib0170]), chronic bacterial prostatitis ([@bib0310]), infective endocarditis ([@bib0158]), pneumonia ([@bib0267]), prosthetic joint infections ([@bib0169]; [@bib0171]; [@bib0106]; [@bib0326]) and urinary tract infections ([@bib0119]). However, there was no specific disease aim in two studies ([@bib0327]; [@bib0101]). One group targeted membrane biofouling for water and wastewater industries ([@bib0004]). Direct bacterial killing, biofilm degradation and dispersal and increased or synergistic therapeutic effectiveness of antimicrobials have been reported as the therapeutic effects of sonobactericide. These studies show that sonobactericide can be applied to treat Gram+ or Gram-- bacteria, when they are planktonic, associated with a surface and embedded in biofilm, or intracellular. The majority of these studies were carried out *in vitro*. However, seven were performed *in vivo* in either mice ([@bib0169]; [@bib0170]; [@bib0267]; [@bib0326]), rats ([@bib0310]) or rabbits ([@bib0171]; [@bib0073]). Sonobactericide was mostly performed with co-administration of antimicrobials. Investigators also employed an antimicrobial encapsulated in liposomes that were conjugated to the microbubbles ([@bib0119]), or the antimicrobial lysozyme was a microbubble coating ([@bib0170]) or did not use antimicrobials altogether ([@bib0004]; [@bib0101]; [@bib0310]). An extensive review of sonobactericide has been published recently by [@bib0159]. Although sonobactericide is an emerging strategy to treat bacterial infections with intriguing potential, the mechanism and safety of the treatment should be explored, particularly with respect to biofilm degradation and dispersal. Future studies should also focus on maximizing the efficacy of sonobactericide *in situ*.

Future perspectives and conclusions {#sec0033}
===================================

Therapeutic ultrasound technology is experiencing a paradigm shift in terms of both technical developments and clinical applications. In addition to its inherent advantages for imaging (*e.g.,* real-time nature, portability and low cost), ultrasound in combination with cavitation nuclei is under exploration as a drug delivery modality. The results from several pre-clinical studies have already illustrated the potential of ultrasound-responsive cavitation nuclei to deliver multiple types of drugs (including model drugs, anticancer drugs, therapeutic antibodies, genes and nanoparticles) efficiently in various tumor models, including both ectopic and orthotopic models, for immunotherapy, brain disease, dissolution of clots and treatment of cardiovascular disease and bacterial infections.

Based on these encouraging pre-clinical data, several clinical trials have been initiated and others are planned. However, whilst animal studies provide proof of concept and impetus for clinical studies, careful attention must be given to their relevance in human disease, in particular, the applicability of therapeutic protocols and appropriate ultrasound settings. Otherwise we risk underestimating the therapeutic effects and potential deleterious side effects. The elucidation of all of the interactions between cavitation nuclei, cells and drugs will help to address this need. The biggest challenges lie in the large differences in time scales between the cavitation initiation, drug release and uptake and a biological response ([Fig. 8](#fig0008){ref-type="fig"}). A multidisciplinary approach is needed to tackle these challenges integrating expertise in physics, biophysics, biology, chemistry and pharmacology.Fig. 8Different time scales of the therapeutic effects of ultrasound and cavitation nuclei treatment. \[Ca^2+^\]~i~ = intracellular calcium; ROS = reactive oxygen species; ATP = adenosine triphosphate; EV = extracellular vesicles. Reprinted (adapted) with permission from [@bib0159].Fig 8

Custom-made microbubbles which serve as cavitation nuclei are often used for ultrasound-mediated drug delivery studies. An advantage is full control over the payload, as well as the disease target. At the same time, full acoustical characterization and sterility of the microbubbles must be considered during translation to human studies, which often requires approval from the U.S. Food and Drug Administration (FDA) or other similar federal agencies in Europe and Asia. As an example, for gene therapy, will each different type of genetic material loaded onto microbubbles need such approval, or will a class of cationic microbubbles be approved regardless of the specific gene? The former path would hinder fast clinical translation. For now, co-administration of drugs with FDA-approved ultrasound contrast agents is being explored in clinical trials. Apart from applications in the brain, ongoing clinical studies evaluating microbubble-mediated drug delivery are based on standard clinical ultrasound scanners operating mostly in Doppler mode. To promote the progress of this emerging technology, it is very important to design and implement specific therapeutic ultrasound pulse sequences that might be vastly different from clinical diagnostic imaging output. Clinical scanners can indeed be modified to be able to generate drug delivery protocols. In a similar way that elastography requires long ultrasound pulses to generate the push sequences ([@bib0061]), ultrasound scanners can be modified to be able to transmit drug delivery ultrasound sequences with tailored and optimized parameters (pulse duration, duty cycle and center frequency).

Ultimately, ultrasound image-guided drug delivery and the monitoring of treatment response could be feasible with the same equipment. Additionally, with recent developments in ultrasound imaging technology, ultrasound-mediated therapy could be planned, applied and monitored in a rapid sequence with high spatial and temporal resolution. The use of a single imaging and therapy device would alleviate the need for co-registration, because the imaging equipment would also be used to induce localized therapy ensuring a perfect co-location. Nonetheless, a compromise between efficacy and safety remains a major challenge for successful clinical applications of this dual methodology, which combines real-time image guidance of therapeutic delivery.

In conclusion, ultrasound-responsive microbubbles which serve as cavitation nuclei are being used to treat a wide variety of diseases and show great potential preclinically and clinically. The elucidation of the cavitation nuclei--cell interaction and the implementation of drug delivery ultrasound sequences on clinical ultrasound scanners are expected to invigorate clinical studies.
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